BioCentury | Sep 19, 2020

Athira, Compass IPOs help quartet push biopharmas’ 2020 NASDAQ haul above $9B

Among a pair of companies that priced upsized IPOs ahead of Friday’s session, neurodegeneration play Athira gave back most of its early gains, while depression company Compass scored a double-digit bump. The deals conclude a...
BioCentury | Sep 12, 2020
Management Tracks

New CEO Hirsch to guide C4 onto NASDAQ; plus Biller adds CFO title at Agios and updates from Sherlock, Lumen and more

...on NASDAQ, where it would become the fourth protein degradation company to list (see “Crossovers Pile...
BioCentury | Aug 11, 2020

Aug. 10 Quick Takes: Megarounds for Lepu, Dyne; plus CureVac’s IPO plans, top marks for Chinese biotech trio and more

...shareholder dievini, has agreed to buy €100 million ($118 million) in a private placement. Crossovers pile...
BioCentury | Aug 4, 2020

Interest in protein degradation runs hot as Kymera files for IPO

...which that firm has invested since 2015 have gone public within a year (see “Crossovers Pile...
BioCentury | Jul 24, 2020

Four more biotech IPOs reach the market, but no big first-day pop in the bunch

Among four new biotech listings Friday, three priced upsized IPOs that each delivered more than $200 million in proceeds, but none of the quartet enjoyed the kind of satisfying first-day pop other biotechs have had...
BioCentury | Jul 16, 2020
Management Tracks

NextCure CMO Heller to resign; plus Vertex, Turning Point, Scholar Rock, C4, Vor and more

...Neon Therapeutics Inc. C4 raised a $150 million series B round in June (see “Crossovers Pile...
BioCentury | Jul 8, 2020

Crossovers pile into $110M series B as Vor heads into the clinic

Vor's $110 million series B round gives the hematopoietic stem cell play enough fuel to keep its financing options open as it advances its lead program into the clinic. RA Capital led the round, which...
BioCentury | Jul 8, 2020

VelosBio jumps on megaround bandwagon with $137M series B

...since filed to go public on NASDAQ (see "Annexon Joins Burgeoning IPO Queue” ; "Crossovers Pile...
BioCentury | Jul 1, 2020

Data Bytes: strategics piling into biotech venture rounds

The number of venture rounds involving corporate VC arms has continued to tick upward. The first half of 2020 has already seen 60 biotech rounds that include participation from at least one corporate VC vs....
BioCentury | Jun 24, 2020

June 23 Quick Takes: Illumina selects first biotechs for U.K. accelerator; plus updates from the NASDAQ IPO queue, and venture rounds for Surrozen, Tara

...bowel disease program (see “TCG Again Backs Surrozen in $50M Series B” ). New investors pile...
Items per page:
1 - 10 of 138